Journal Of Chemotherapy

SCI SCIE

国际简称：J CHEMOTHERAPY 参考译名：化疗杂志

主要研究方向：医学-药学非预警期刊审稿周期：较慢,6-12周

《化疗杂志》(Journal Of Chemotherapy)是一本由Maney Publishing出版的以医学-药学为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

4区中科院分区
Q3 JCR分区
73 年发文量
2.1 IF影响因子
未开放 是否OA
45 H-index
1989 创刊年份
Bimonthly 出版周期
English 出版语言

The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.

The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.

Specific areas of focus include, but are not limited to:

· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;

· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;

· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;

· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;

· Drug interactions in single or combined applications;

· Drug resistance to antimicrobial and anticancer drugs;

· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;

· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;

· Pharmacogenetics and pharmacogenomics;

· Precision medicine in infectious disease therapy and in cancer therapy;

· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.

[ 查看全部 ]

投稿咨询加急咨询

Journal Of Chemotherapy期刊信息

ISSN：1120-009X
出版语言：English
是否OA：未开放
E-ISSN：1973-9478
出版地区：ITALY
是否预警：否
出版商：Maney Publishing
出版周期：Bimonthly
创刊时间：1989
开源占比：0.0164
Gold OA文章占比：4.68%
OA被引用占比：0.0468...
出版国人文章占比：0.11
出版撤稿占比：0
研究类文章占比：84.93%

Journal Of Chemotherapy CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

4.1

0.525

0.545

学科类别	分区	排名	百分位
大类：Medicine 小类：Infectious Diseases	Q2	159 / 361	56%
大类：Medicine 小类：Pharmacology (medical)	Q2	133 / 278	52%
大类：Medicine 小类：Oncology	Q3	215 / 428	49%
大类：Medicine 小类：Pharmacology	Q3	181 / 328	44%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Journal Of Chemotherapy中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	ONCOLOGY 肿瘤学 INFECTIOUS DISEASES 传染病学 PHARMACOLOGY & PHARMACY 药学	4区 4区 4区

Journal Of Chemotherapy JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：INFECTIOUS DISEASES	SCIE	Q3	95 / 141	33
学科：ONCOLOGY	SCIE	Q3	236 / 333	29.3
学科：PHARMACOLOGY & PHARMACY	SCIE	Q3	240 / 356	32.7
学科：INFECTIOUS DISEASES	SCIE	Q3	92 / 141	35.11
学科：ONCOLOGY	SCIE	Q3	210 / 333	37.09
学科：PHARMACOLOGY & PHARMACY	SCIE	Q3	218 / 356	38.9

Journal Of Chemotherapy历年数据统计

影响因子

中科院分区

Journal Of Chemotherapy中国学者发文选摘

1、Disseminated intravascular coagulation (DIC) associated with immune checkpoint inhibitor therapy: a real-world study of the FDA adverse event reporting syste
Author: Yang, Xia; Hu, Ming; Feng, Quanyao; Mo, Diwei; Feng, Fuzhen; Lei, Luwen; Pan, Xingxi

Journal: JOURNAL OF CHEMOTHERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/1120009X.2026.2646812
2、Analysis of risk factors for infusion-related reactions in patients with B-cell lymphoma during obinutuzumab treatmen
Author: Wang, Zi; Zhang, Yan; Zhao, Danqing; Wei, Chong; Wang, Wei; Zhou, Daobin; Zhang, Wei

Journal: JOURNAL OF CHEMOTHERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/1120009X.2026.2640329
3、Biliary disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) databas
Author: Wei, Shiju; Zhang, Zhenyu; Song, Xuhua; Chen, Rui; Chen, Siyu; Lu, Baoping

Journal: JOURNAL OF CHEMOTHERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/1120009X.2025.2612386
4、Safety analysis of vinorelbine in the real world: a pharmacovigilance study based on the FAERS databas
Author: Li, Yuhui; Shi, Zheng; Fu, Xiaoshuang; Si, Han; Song, Haolin; Fei, Yuchen; Wang, Ziqi; Wu, Qin; Song, Zhengbo

Journal: JOURNAL OF CHEMOTHERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/1120009X.2025.2612385
5、Cinobufagin regulates the microRNA-149-3p/AFF4 axis to affect the proliferation and apoptosis of cisplatin-resistant ovarian cancer cell
Author: Liu, Yunfei; Chen, Taoli; Wang, Yanpeng; Gao, Yuanyuan; Xie, Ning; Xia, Wanping; Wang, Qichuan

Journal: JOURNAL OF CHEMOTHERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/1120009X.2025.2508614
6、Identification of synthetic lethality-associated subtypes and construction of risk model to predict breast cancer prognosis and immune characteristic
Author: Tang, Jianhong; Chen, Weihong; Zou, Weibao; Cao, Shujuan

Journal: JOURNAL OF CHEMOTHERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/1120009X.2025.2512263
7、NCAPG2 promotes the proliferation, metastasis and resistance to nab-paclitaxel in gastric adenocarcinoma cell
Author: Xu, Jia; Liu, Xiaoyuan; Huang, Zebo; Zhang, Ying; Li, Xia; Cai, Dongyan

Journal: JOURNAL OF CHEMOTHERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/1120009X.2025.2498230
8、Real-world effectiveness and safety of meropenem-vaborbactam in the treatment of carbapenem-resistant enterobacterales (CRE) infections: a systematic review and meta-analysi
Author: Jin, Dongcai; Hu, Danyang; Jin, Yuhong

Journal: JOURNAL OF CHEMOTHERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/1120009X.2025.2465129